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ABSTRACT
Oncogenic Ras signalling occurs frequently in many human cancers. However, 
no effective targeted therapies are currently available to treat patients suffering from 
Ras-driven tumours. Therefore, it is imperative to identify downstream effectors of Ras 
signalling that potentially represent promising new therapeutic options. Particularly, 
considering that autophagy inhibition can impair the survival of Ras-transformed cells 
in tissue culture and mouse models, an understanding of factors regulating the balance 
between autophagy and apoptosis in Ras-transformed human cells is needed. Here, 
we report critical roles of the STK38 protein kinase in oncogenic Ras transformation. 
STK38 knockdown impaired anoikis resistance, anchorage-independent soft agar 
growth, and in vivo xenograft growth of Ras-transformed human cells. Mechanistically, 
STK38 supports Ras-driven transformation through promoting detachment-induced 
autophagy. Even more importantly, upon cell detachment STK38 is required to sustain 
the removal of damaged mitochondria by mitophagy, a selective autophagic process, 
to prevent excessive mitochondrial reactive oxygen species production that can 
negatively affect cancer cell survival. Significantly, knockdown of PINK1 or Parkin, 
two positive regulators of mitophagy, also impaired anoikis resistance and anchorage-
independent growth of Ras-transformed human cells, while knockdown of USP30, 
a negative regulator of PINK1/Parkin-mediated mitophagy, restored anchorage-
independent growth of STK38-depleted Ras-transformed human cells. Therefore, 
our findings collectively reveal novel molecular players that determine whether Ras-
transformed human cells die or survive upon cell detachment, which potentially could 
be exploited for the development of novel strategies to target Ras-transformed cells.
INTRODUCTION
Cancer progression is subdivided into different 
major steps leading to malignant transformation and 
consequently the formation of aggressive tumours [1]. 
Two key steps and hallmarks of malignant cancer cells 
are resistance to anoikis (cell detachment-induced 
apoptosis [2]) and anchorage-independent growth [3]. 
Tumour cells use different strategies to circumvent 
anoikis [3]. For example, a compensatory strategy is the 
constitutive activation of pro-survival signals through pro-
tumourigenic pathways such as Ras signalling, while an 
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alternative strategy is the activation of cellular processes 
such as detachment-induced macroautophagy, which 
enables tumour cells to survive stress associated with 
extracellular matrix (ECM) detachment [4]. Whatever 
the mechanism to acquire anoikis resistance, the main 
consequence is the loss of anchorage-dependent growth, 
enabling detached tumour cells to proliferate, invade 
adjacent tissues, and hence potentially spread through the 
body [3].
Macroautophagy (henceforth termed autophagy) is 
a physiological mechanism for cell survival under stress 
conditions. During normal cell homeostasis, autophagy 
acts as a catabolic process to promote the degradation 
of potentially toxic protein aggregates and damaged 
organelles by encasing them in specialized intracellular 
autophagosomal vesicles for subsequent break down by 
lysosomal proteases for recycling [5]. Upon stress, the 
rate of autophagy increases to support survival, growth 
and metabolism [6]. Consequently, the modulation of 
autophagy is recognised as a hallmark of human cancer 
cells with context-dependent functions [7, 8]. Upon cancer 
initiation, autophagy may be tumour suppressive, while 
at advanced cancer stages autophagy tends to support 
malignant transformation by promoting survival of ECM-
detached cancer cells [4, 9]. However, the signalling 
mechanisms controlling detachment-induced autophagy 
are not fully understood [4].
The small GTPase family of Ras proteins are 
frequently mutated proto-oncogenes in human cancers 
with a high prevalence in colorectal, pancreatic and lung 
cancers, where cancers carrying activating mutations in 
Ras are linked to particularly poor prognosis [10]. Thus, 
the selective targeting of downstream effectors of Ras 
signalling has seen substantial research investments. 
However, no effective targeted therapies currently exist 
for patients with tumours carrying mutant Ras. A recent 
example is MAPK pathway inhibition, where MEK 
inhibitor therapy is largely ineffective in individuals 
carrying oncogenic Ras mutations [11, 12]. Thus, there is 
a need to uncover molecular targets that potentially can 
be exploited to develop new therapeutic strategies for the 
targeted treatment of Ras-driven tumours. In this regard, 
mouse data indicate that tumours expressing oncogenic 
Ras can depend on autophagy for survival [13–18], 
suggesting that Ras-driven tumours can be “autophagy 
addicted” [13]. In support of this “autophagy addiction” 
model, it was reported that autophagy is required for 
robust anchorage-independent growth of Ras-transformed 
human cells [9, 13, 19, 20]. Thus, these preclinical 
studies suggest that autophagy is critical for malignant 
transformation through activated Ras, hence proposing 
that acute autophagy inhibition may be therapeutically 
beneficial in Ras-driven cancers. However, we currently 
do not fully understand whether the inhibition of a specific 
type of autophagy is sufficient to impair the survival of 
Ras-transformed cells. For example, it was reported that 
mitophagy, a selective autophagic processes targeting 
specifically mitochondria [21–23], can maintain the pool 
of functional mitochondria necessary to support growth 
of Ras-driven tumours [13, 24], while Ras-induced 
autophagy can mediate the functional loss of mitochondria 
during transformation [25]. Thus, the role of mitophagy in 
Ras-transformed human cells is incompletely understood.
Here, we report that the survival of Ras-transformed 
human cells is dependent on the STK38 (aka NDR1) 
serine/threonine protein kinase [26, 27]. More specifically, 
we define novel cancer cell biology roles of STK38 as a 
facilitator of pro-survival mechanisms in Ras-driven 
transformation. Considering that STK38 was recently 
linked as a pro-apoptotic kinase to possibly tumour 
suppressive activities in adherent cells [28–32], we had 
hypothesized that STK38 might play a role in opposing 
Ras-mediated malignant transformation by promoting 
apoptosis in stress conditions. However, to our surprise, 
we found that STK38 supports the survival of Ras-
transformed human cells upon cell detachment. Given 
this observation and that our research recently revealed 
that STK38 positively promotes autophagy in adherent 
cells [29], we therefore postulated that STK38-mediated 
autophagy might support anoikis resistance and/or 
anchorage-independent growth in Ras-transformed 
cells. Indeed, STK38 knockdown resulted in diminished 
detachment-induced autophagy and anchorage-
independent growth, paralleled by increased anoikis. We 
further found that STK38 potentially contributes to the 
survival of Ras-transformed human cells by supporting 
mitophagy. Knockdown of PINK1 or Parkin, the two 
best characterised regulators of mitophagy [22, 23], also 
impaired anoikis resistance and anchorage-independent 
growth of Ras-transformed human cells. Collectively, 
these findings uncover that regulators of mitophagy can 
determine whether Ras-transformed cells die or survive 
upon cell detachment, which could be exploited for the 
development of novel strategies to treat Ras-transformed 
cancer cells.
RESULTS
The STK38 kinase supports Ras-induced 
transformation of human cells
To understand whether STK38 plays a role in Ras-
mediated transformation of human cells, we initially 
selected HK-HT cells, since they are a well-defined cell 
system for studying Ras-driven malignant transformation 
by soft agar colony formation and xenograft tumour 
growth [33–37]. As anticipated, HK-HT cells were 
transformed upon expression of oncogenic H-RasG12V 
as evidenced by growth in soft agar (Supplementary 
Figure S1). To test whether STK38 signalling plays a role 
in this setting, we assessed the consequences of STK38 
depletion using three different siRNAs (Figure 1) and 
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Figure 1: STK38 is required for anchorage independent growth and tumourigenicity of HRas-transformed human 
cells. A, D. Immunoblotting with indicated antibodies of cell lysates derived from H-RasG12V-transformed HK-HT cells (HK-HRasG12V) 
transiently transfected for 72 hrs with indicated siRNAs. Densitometry quantifications of immunoblots are indicated below the 
immunoblots. B, C, E, F. Depletion of STK38, but not STK38L, decreases anchorage-independent growth of HK-HRasG12V cells. Cells 
transiently transfected with indicated siRNAs were subjected to soft agar growth assays. Representative images of soft agar assays (B, 
E). Quantifications of colony formation in soft agar (C, F). The average of three experiments performed in duplicates is shown (n=3, 
***p<0.001; ns, not significant). G-I. STK38 kinase activity is necessary for anchorage independent growth of HK-HRasG12V cells. (G) 
Western blot analysis of cells stably co-expressing indicated shRNAs with empty vector (EV), RNAi-resistant HA-tagged STK38 wild-type 
(wt) or kinase-dead (kd). Densitometry quantifications of immunoblots are indicated below the immunoblots (G). Cells were subjected to 
soft agar growth assays. Representative images (H). Quantification of colony formation in soft agar (I). The average of three experiments 
performed in duplicates is shown (n=3, *p<0.05; **p<0.01). J-M. STK38 is critical for the tumourigenicity of HK-HRasG12V cells. 
Immunoblotting of cells stably expressing indicated shRNAs (J). Densitometry quantifications of immunoblots are indicated below the 
immunoblots (J). Tumour formation of xenografts was monitored by volume changes (K). After animal euthanasia, STK38 depletion was 
analysed in tumour samples (L) and the tumour weight determined (M). Data represent the average of 12 mice per group (***p<0.001).
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overexpression of hyperactive STK38-PIF (Supplementary 
Figure S1). This revealed that HK-HT cells expressing 
oncogenic HRasG12V (henceforth called HK-
HRasG12V) with transient STK38 depletion displayed 
significantly decreased soft agar colony formation 
(Figure 1A, 1B, 1C), while expression of hyperactive 
STK38-PIF [38] was not sufficient to transform HK-
HT cells (Supplementary Figure S1). Although human 
STK38L (aka NDR2) is similar to human STK38 [26, 
27], efficient STK38L depletion in HK-HRasG12V had 
no effect on anchorage-independent growth (Figure 1D, 
1E, 1F). To test whether STK38 kinase activity plays a 
role in supporting oncogenic Ras-mediated tumourigenic 
growth, we generated HK-HRasG12V cells stably 
expressing STK38-targeted shRNAs together with empty 
vector (EV), RNAi-resistant HA-STK38 wild-type (wt), 
or RNAi-resistant HA-STK38 kinase-dead (kd) (Figure 
1G). As shown in Figure 1H and 1I, expression of HA-
STK38(wt) substantially restored anchorage-independent 
growth, while cells expressing EV or HA-STK38(kd) 
did not compensate for the loss-of-function of STK38. 
These findings argue that STK38 kinase activity supports 
the anchorage-independent growth of Ras-transformed 
human cells. To validate whether STK38 also has a critical 
function in promoting Ras-induced tumourigenesis in vivo, 
we injected HK-HRasG12V cells stably expressing control 
or STK38-targeted shRNAs (Figure 1J) as xenografts into 
nude mice and monitored tumour formation (Figure 1K). 
This revealed that STK38-depleted tumours (Figure 1L) 
displayed markedly decreased growth as judged by volume 
(Figure 1K) and weight (Figure 1M). Taken together, our 
data presented in Figure 1 indicate that the STK38 kinase 
supports key oncogenic features of Ras-transformed HK-
HT cells, namely colony formation in soft agar and in vivo 
xenograft tumour growth.
To investigate whether STK38 also promotes 
anchorage-independent growth of human cancer cells 
carrying endogenous activating mutations of Ras, we 
depleted STK38 in HCT116 (colorectal carcinoma cell line 
expressing KRasG13D), Panc1 (pancreatic adenocarcinoma 
cell line carrying KRasG12D), H1299 (lung carcinoma cell 
line expressing NRasQ61K), and T24 cells (urinary bladder 
carcinoma cell line carrying HRasG12V) (Figure 2). This 
revealed that STK38-depleted HCT116, Panc1, H1299 and 
T24 cells (Figure 2A) displayed significantly decreased 
anchorage-independent growth (Figure 2B, 2C), suggesting 
that STK38 plays a critical part in anchorage-independent 
growth of Ras-transformed human cells of diverse origins 
expressing different oncogenic Ras versions.
p21/Cip1 upregulation in STK38-depleted Ras-
transformed cells does not suppress anchorage-
independent growth
In addition to soft agar growth (Supplementary 
Figure S1), HK-HRasG12V displayed anoikis resistance 
as judged by proliferation in suspension associated with 
reduced apoptosis upon cell detachment as assessed by 
PARP cleavage (Supplementary Figure S2A, S2B, S2C). 
STK38 depletion in HK-HRasG12V impaired proliferation 
in suspension (Figure 3A), accompanied by changes in the 
sub-G1, G1/S and G2/M cell cycle phases (Figure 3B). 
Considering that STK38 can regulate the G1/S transition 
through controlling p21CDKN1A protein levels [39], we 
hypothesized that STK38 might support pro-survival 
oncogenic Ras signalling by suppressing p21 stabilisation. 
As anticipated [39], STK38 silencing in detached HK-
HRasG12V resulted in significantly increased p21 protein 
levels (Figure 3C). However, upon knockdown of p21 
together with STK38 in HK-HRasG12V (Figure 3D), 
soft agar growth was not increased when compared to 
cells with single knockdown of STK38 (Figure 3E and 
3F). To consolidate this finding, KRasG13D-driven 
HCT116 cells with homozygous deletion of p21 [40] were 
analysed, revealing that STK38 depletion in p21-null 
HCT116 cells resulted in significantly reduced anchorage-
independent growth (Figure 3G, 3H, 3I). Taken together, 
these observations suggest that STK38 can promote 
anchorage-independent growth of Ras-transformed cells 
independently of p21.
STK38 supports detachment-induced autophagy 
and anoikis resistance in Ras-transformed 
human cells
Considering that detachment-induced autophagy 
can promote anchorage-independent growth of Ras-
transformed cells [4], we explored whether the role of 
STK38 as autophagy regulator [29] might contribute to 
anchorage-independent growth of Ras-transformed human 
cells. Similar as reported for HCT116, Panc1 and H1299 
[9, 13, 20], we observed that HK-HRasG12V displayed 
elevated detachment-induced autophagy (Figure 4A, 4B, 
Supplementary Figure S2D, S2E) as assessed by conversion 
of LC3B-I to LC3B-II [41]. To visualise autophagic flux, 
LC3B was monitored in the presence of chloroquine 
(CQ), blocking lysosomal degradation of autophagosome 
contents. Detachment-induced changes of LC3B-II levels 
in HK-HRasG12V were at least in part Beclin1 dependent 
(Supplementary Figure S3). Moreover, in agreement with 
experiments studying other Ras-driven cancer cells [9, 13, 19, 
20], genetic and pharmacological inhibition of autophagy in 
HK-HRasG12V resulted in decreased anchorage-independent 
growth (Supplementary Figure S4). Collectively, these 
findings demonstrate that HK-HRasG12V rely on autophagy 
for growth and survival in anchorage-independent conditions, 
hence establishing HK-HRasG12V as an excellent model 
system to explore the possible involvement of STK38-
mediated autophagy in the survival and growth of detached 
Ras-transformed human cells.
As expected, STK38 depletion in adherent HK-
HRasG12V cells resulted in reduced autophagy activity 
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(Figure 4C, 4D) as evidenced by the LC3B-II conversion 
assay [41]. Significantly, detachment-induced autophagy 
was also diminished upon STK38 depletion in HK-
HRasG12V (Figure 4C, 4D, Supplementary Figure S5). 
STK38 knockdown also reduced detachment-induced 
autophagy in HCT116 cells (Supplementary Figure S6A, 
S6B). As an alternative approach, LC3B puncta were 
analysed by immunofluorescence, an established readout 
for autophagosome formation [41], revealing that the 
number of autophagosomes was notably decreased upon 
STK38 knockdown (Figure 4E, 4F, 4G). Cumulatively, 
these data indicate that detachment-induced autophagy is 
mediated at least partly by STK38, and that this activity 
may protect Ras-transformed human cells from anoikis.
While HK-HT deprived of proper ECM contact 
underwent anoikis, HK-HRasG12V displayed anoikis 
resistance (Supplementary Figure S2A, S2B, S2C). 
Thus, we next tested whether STK38 promotes anoikis 
resistance in Ras-transformed cells. Intriguingly, detached 
STK38-depleted HK-HRasG12V displayed an increase 
in the sub-G1 cell cycle phase (Figure 3B), suggesting 
that STK38 depletion caused increased cell death. To 
examine whether this cell death was at least partly due 
to anoikis, we measured two independent markers of 
apoptosis, namely Annexin V staining by flow cytometry 
(Figure 4H, 4I, 4J) and PARP cleavage by immunoblotting 
(Figure 4K, 4L). Significantly, these analyses revealed that 
STK38-depleted HK-HRasG12V displayed dramatically 
Figure 2: STK38 supports the anchorage independent growth of Ras-driven human cancer cell lines. A. Western blotting 
with indicated antibodies of cell lysates transiently transfected for 72 hrs with indicated siRNAs. The mutation status of endogenous Ras 
isoforms is shown. Densitometry quantifications of immunoblots are displayed below the immunoblots. B. Cells transiently transfected 
with indicated siRNAs were subjected to soft agar growth assays. Representative images are displayed. C. Quantifications of colony 
formation in soft agar. The average of three experiments performed in duplicates is shown (n=3, *p<0.05; **p<0.01; ***p<0.001.
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Figure 3: p21 upregulation in STK38-depleted Ras-transformed cells does not suppress anchorage-independent 
growth. A. Proliferation rates of detached HK-HRasG12V cells transiently transfected with indicated siRNAs. The average of three 
experiments performed in duplicates is shown (n=3, **p<0.01). Validation of STK38 knockdown is shown as insert. B. Cell cycle analyses 
of detached HK-HRasG12V cells transiently transfected with indicated siRNAs. After 16 hrs in suspension, cells were processed for flow 
cytometry. One of three experiments is shown. Validation of STK38 depletion is shown as insert. C. Immunoblotting of HK-HRasG12V 
lysates transiently transfected with indicated siRNAs. Cells grew for 16 hrs in suspension before lysis. One of three experiments is shown 
(top panel). Densitometry quantification of immunoblots (bottom panel, n=3, *p<0.05; **p<0.01). D-F. Western blots of cells transiently 
transfected with indicated siRNAs (D). Densitometry quantifications of immunoblots are shown below the immunoblots (D). Cells were 
analysed by soft agar growth assays. Representative images (E). Quantification of colony formation in soft agar (F). The average of three 
experiments performed in duplicates is shown (n=3, ***p<0.001. G-I. Immunoblotting of cell lysates derived from parental and p21-null 
(p21-/-) HCT116 cells transiently transfected with the indicated siRNAs (G). Densitometry quantifications of immunoblots are specified 
below the immunoblots (G). Cells were subjected to soft agar growth assays. Representative images (H). Quantification of colony formation 
in soft agar (I). The average of three experiments performed in duplicates is shown (n=3, *p<0.05; **p<0.01).
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Figure 4: STK38 supports detachment-induced autophagy and anoikis resistance. A, B. Immunoblot analysis of HK-
HRasG12V cells grown in attached (A) or suspended (S) conditions with (+) or without (-) chloroquine (CQ). Lipidated (LC3B-II) and 
non-lipidated (LC3B-I) LC3B is indicated. One of three experiments is shown (A). Densitometry quantification of immunoblots (B, n=3, 
**p<0.01). C, D. Western blot analysis of cells transiently transfected with indicated siRNAs and grown in attached (A) or suspended (S) 
conditions with or without CQ. One of three experiments is shown (C). Densitometry quantification of immunoblots (D, n=3, **p<0.01; 
***p<0.001). E-G. Immunoblots of cells transiently transfected with indicated siRNAs (E). Cells grown in suspension for 16 hrs in the 
presence of CQ were subjected to immunofluorescence analysis (F). LC3B is green. DNA is blue. Scale bar: 10 µm. Quantification of LC3 
puncta per cell (G, at least 60 cells were analysed per condition, n=3, *p<0.05). H-J. Western blot analysis of cells transiently transfected 
with indicated siRNAs (H). Detached cells were processed for flow cytometry using AnnexinV-FITC and propidium iodide (PI) co-staining. 
One representative result is shown (I). Coloured rectangles and numbers indicate the number of apoptotic cells. Quantifications of apoptotic 
cells (J, n=3, *p<0.05; ***p<0.001). K, L. Immunoblot of detached cells transiently transfected with indicated siRNAs (K). One of three 
experiments is shown. Densitometry quantification of immunoblots (L, n=3, **p<0.01; ***p<0.001). M, N. Western blots of lysates 
derived from cells grown in attached (A) or suspended (S) conditions (M). Densitometry quantification of immunoblots (N, n=3, **p<0.01).
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elevated levels of anoikis when grown in suspension. 
Depletion of Beclin1, a key regulator of autophagy [42], 
also caused increased anoikis (Supplementary Figure S7) 
and interfered with anchorage-independent growth of HK-
HRasG12V (Supplementary Figure S4). Considering that 
Beclin1 can function upstream of STK38 upon autophagy 
induction [29], these observations further strengthen 
the notion that STK38-mediated detachment-induced 
autophagy is critical to support oncogenic Ras signalling 
in order to antagonise anoikis and subsequently to promote 
anchorage-independent growth. In full agreement with this 
concept, we also detected considerably elevated STK38 
kinase activity upon detachment of HK-HRasG12V cells 
(Figure 4M, 4N), as assessed by Thr444 phosphorylation 
of STK38, an established readout for STK38 kinase 
activity [27].
Ral signalling supports detachment-induced 
autophagy and anoikis resistance in Ras-
transformed human cells
Ral-Exocyst signalling promotes anchorage-
independent growth in HK-HRasG12V cells [34–37] 
and supports autophagy in adherent cells [43]. Therefore, 
we postulated that STK38 might act in Ras-mediated 
transformation by functioning downstream of Ras-
Ral-Exocyst signalling. To test this idea, we pursued 
different experimental avenues. First, we tested STK38 
depletion in HK-HT expressing a HRasG12V/E37G 
mutant [44], which mainly activates RalGEFs, while 
only weakly stimulating Raf or PI3-kinase signalling [34] 
(Supplementary Figure S8A, S8B, S8C). As anticipated 
[34], the HRasG12V/E37G mutant transformed HK-
HT (Supplementary Figure S8D, S8E). Noteworthy, 
STK38 depletion in HK-HRasG12V/E37G (Figure 5A) 
reduced growth of colonies in soft agar (Figure 5B, 5C), 
suggesting that STK38 can function downstream of Ral 
signalling. Secondly, depletion of RalA or RalB in HK-
HRasG12V, which appears to affect both Ral proteins to 
some degree (Figure 5D), confirmed their involvement in 
anchorage-independent growth (Figure 5E, 5F). Thirdly, 
knockdown of the Exocyst components Sec5 or Exo84 in 
HK-HRasG12V also indicated that the Exocyst complex 
is critical to sustain anchorage-independent growth 
(Supplementary Figure S9). Taken together, these data 
demonstrate that Ral-Exocyst signalling significantly 
contributes to Ras-mediated transformation in HK-HT 
cells.
Next, to further examine whether STK38 acts 
downstream of Ral signalling, we investigated the 
consequences of RalA or RalB depletion on Thr444 
phosphorylation of STK38, detachment-induced 
autophagy, and anoikis resistance. RalA or RalB 
knockdown in HK-HRasG12V significantly decreased 
detachment-induced Thr444 phosphorylation of STK38 
(Figure 5G, 5H). Similar to results obtained with 
STK38-depleted cells (Figure 4C, 4D, Supplementary 
Figure S5), LC3B-II conversion assays showed reduced 
detachment-induced autophagy in RalA- or RalB-depleted 
HK-HRasG12V (Figure 5I, 5J). RalB depletion seems to 
lead to increased anoikis (Figure 5K, 5L, 5M), although 
to a much lesser degree than observed upon STK38 
knockdown (Figure 4H, 4I, 4J). In contrast, RalA depletion 
appears to have no detectable effect on anoikis resistance 
(Figure 5K, 5L, 5M), although these effects of single RalA 
or RalB depletions have to be interpreted with caution, 
since they may affect the levels of both Ral proteins in 
our settings (Figure 5K). In summary, these data suggest 
that Ral signalling at least partly supports Ras-driven 
transformation through the STK38 kinase as a downstream 
effector.
STK38 is required for mitochondrial clearance 
in Ras-transformed human cells
The main cancer-promoting roles of autophagy are 
the preservation of organelle function and the provision 
of energy substrates. Current evidence suggests that 
inhibition of mitophagy, which selectively targets damaged 
(depolarized) mitochondria for degradation by autophagy 
[23], can promote tumour progression and does not 
phenocopy inhibition of autophagy [22]. However, like 
autophagy, mitophagy may have context-dependent roles 
in cancer. For example, mitophagy maintains the pool of 
functional mitochondria necessary to support growth of 
Ras-driven tumours [13, 24], while Ras-induced autophagy 
can mediate the functional loss of mitochondria during 
transformation [25]. In this regard, it is intriguing that 
STK38 can act in mitochondrial quality control [45] in 
addition to its role in non-selective autophagy [29]. However, 
whether the STK38-mediated mitochondrial quality control 
pathway plays any role in cellular transformation is currently 
unknown. Thus, we tested whether STK38 can play a role 
in mitophagy in detached Ras-transformed human cells by 
studying different mitochondrial parameters (Figure 6A, 
6B, 6C, Supplementary Figure S6, S10). First, we measured 
changes in mitochondrial mass using a membrane potential-
independent MitoTracker (Figure 6A, Supplementary 
Figure S6C, S10A, S10C, S10D). Second, the levels 
of the non-respiratory outer mitochondrial membrane 
protein TOM20 and five inner mitochondrial membrane 
proteins were analysed (Figure 6B, Supplementary Figure 
S6D, S10E, S10F). Third, we used the JC-1 dye as an 
indicator of mitochondrial membrane potential (Figure 
6C, Supplementary Figure S10G). These measurements 
collectively revealed that STK38-depleted Ras-transformed 
human cells displayed increased mitochondrial mass 
associated with decreased mitochondrial membrane 
potential, suggesting that in Ras-transformed cells STK38 
is required to ensure the removal of damaged mitochondria. 
To confirm that the observed changes in mitochondrial 
mass are a consequence of decreased mitophagy, we 
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Figure 5: Ral GTPases support anchorage-independent growth and detachment-induced autophagy at least partly 
through STK38 as effector. A-C. Immunoblotting of HK-HRasG12V/E37G lysates transiently transfected with indicated siRNAs 
(A). Densitometry quantifications of immunoblots are indicated below the immunoblots (A). Cells were tested by soft agar growth assays. 
Representative images (B). Quantification of colony formation in soft agar (C). The average of three experiments performed in duplicates 
is shown (C, n=3, *p<0.05; **p<0.01). D-F. Immunoblotting of HK-HRasG12V lysates transiently transfected with indicated siRNAs (D). 
Densitometry quantifications of immunoblots are shown below the blots (D). Cells were analysed by soft agar growth assays. Representative 
images (E). Quantification of colony formation in soft agar (F). The average of three experiments performed in duplicates is shown (F, n=3, 
*p<0.05; **p<0.01). G, H. Immunoblotting of lysates transiently transfected with indicated siRNAs and grown in attached (A) or suspended 
(S) conditions (G). Densitometry quantification of immunoblots (H, n=3, *p<0.05). I, J. Western blots of lysates of HK-HRasG12V cells 
transiently transfected with indicated siRNAs and grown in suspension with or without CQ (I). Densitometry quantification of immunoblots 
(J, n=3, *p<0.05; **p<0.01). K-M. Immunoblotting of cells transiently transfected with indicated siRNAs (K). Densitometry quantifications 
of immunoblots are indicated below the blots (K). Cells were grown in suspension for 16 hrs before processing for flow cytometry using 
AnnexinV-FITC and propidium iodide (PI) co-staining. One representative result is shown (L). Rectangles and numbers indicate the 
number of apoptotic cells. Quantifications of the percentage of apoptotic cells (M, n=3, *p<0.05; ns, not significant).
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pharmacologically and genetically inhibited autophagy. 
This revealed that autophagy inhibition by either CQ 
treatment or ATG5 knockdown resulted in significantly 
increased mitochondrial mass in detached HK-HRasG12V 
(Supplementary Figure S11A, S11B). Moreover, PINK1 
depletion in detached HK-HRasG12V cells caused impaired 
mitophagy (Supplementary Figure S11C), while autophagy 
in general was not affected as judged by LC3B-II conversion 
assays (Supplementary Figure S12).
Noteworthy, upon cell detachment STK38-depleted 
HK-HRasG12V cells (Supplementary Figure S10B) 
displayed significantly elevated levels of reactive oxygen 
species (ROS) (Figure 6D), with mitochondrial ROS being 
considerably elevated (Figure 6E). Thus, we tested next 
Figure 6: STK38 supports the clearance of damaged mitochondria to prevent ROS-mediated anoikis in detached Ras-
transformed human cells. A-E. Cells transiently transfected with indicated siRNAs and grown in suspension were subjected to flow 
cytometry (A, C, D, E) and immunoblotting (B, C) using indicated dyes and antibodies. One of three experiments is shown. Quantifications 
of total mitochondrial mass (A), densitometry of immunoblots (B), mitochondrial membrane potential (C), intracellular ROS levels (D) and 
mitochondrial ROS levels (E). (A-E, n=3, *p<0.05; **p<0.01). Validation of STK38 knockdown is shown as insert (C) or is presented in 
Supplementary Figures S10A and S10B. F. Cells were transiently transfected with indicated siRNAs and subsequently grown in suspension 
in the absence (-) or presence (+) of N-acetylcysteine (NAC), followed by processing for immunoblotting. One of three experiments is 
shown (top panel). Quantifications of densitometry of immunoblots (bottom panel, n=3, *p<0.05).
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whether elevated ROS production due to STK38 depletion 
caused increased cell death of Ras-transformed human 
cells. To do so, detached STK38-depleted HK-HRasG12V 
and HCT116 cells were treated with the ROS inhibitor 
N-acetyl-L-cysteine (NAC) and cell death was monitored 
by PARP cleavage (Figure 6F, Supplementary Figure S6E, 
S6F). Significantly, NAC treatment of STK38-depleted HK-
HRasG12V and HCT116 cells at least in part decreased PARP 
cleavage in Ras-transformed human cells. Taken together, 
these findings suggest that STK38 supports the removal of 
damaged mitochondria by mitophagy to limit potentially 
toxic ROS production in detached Ras-transformed cells, 
which in turn can promote anoikis resistance and anchorage-
independent growth of Ras-transformed cells.
Considering that our data (Figure 5, Supplementary 
Figure S8) indicate that the Ral pathway supports Ras-
mediated transformation through STK38 as a downstream 
effector, we wondered next whether Ral signalling 
contributes to mitophagy in Ras-transformed cells. Thus, 
we monitored changes in mitochondrial mass upon 
knockdown of these signalling components in detached 
HK-HRasG12V cells (Supplementary Figure S13). This 
revealed that RalB-depleted cells displayed a significant 
increase in mitochondrial mass in contrast to control 
and RalA-depleted cells (Supplementary Figure S13). 
These findings suggest that RalB signalling contributes to 
mitophagy in Ras-transformed cells, while RalA signalling 
appears to be dispensable for mitophagy.
Finally, we wondered whether, similar to STK38, 
other regulators of mitophagy also support the survival 
of Ras-transformed human cells. Specifically, since 
mitophagy is regulated in many cell types by Parkin and 
PINK1 [22, 23] and loss of PINK1 can impair cancer-
associated phenotypes including anchorage-independent 
growth of HeLa cells [46], we speculated that PINK1 
and/or Parkin might play a role in promoting soft agar 
growth of Ras-transformed human cells. Indeed, PINK1 or 
Parkin depletion in HK-HRasG12V dramatically reduced 
soft agar growth, associated with increased anoikis as 
judged by elevated PARP cleavage (Figure 7A, 7B, 7C, 
Supplementary Figure S14A, S14B). Therefore, our data 
collectively suggest that the STK38 and PINK1/Parkin 
mitochondrial quality control pathways play an important 
role in Ras-induced malignant transformation.
To test whether the STK38 and PINK1/Parkin 
pathways are genetically linked in our settings, we studied 
the consequences of STK38 depletion combined with 
knockdown of USP30, a negative regulator of mitophagy 
that opposes PINK1/Parkin-mediated mitophagy [47, 48]. 
More precisely, the USP30 deubiquitinase can inhibit 
the mitophagic process by opposing the ubiquitination 
of mitochondrial proteins by the Parkin E3 ubiquitin 
ligase. In this regard, we speculated that USP30 depletion 
might compensate for STK38 deficiency, hence restoring 
anchorage-independent growth of STK38-depleted Ras-
transformed cells. This final set of experiments showed 
that the knockdown of USP30 alone (Figure 7D) had no 
significant effect on the anchorage-independent growth 
of HK-HRasG12V cells (Figure 7E, 7F). Importantly, co-
depletion of STK38 and USP30 (Figure 7D) resulted in 
a partial restoration of anchorage-independent growth of 
Ras-transformed human cells when compared to single 
STK38 knockdown (Figure 7E, 7F), suggesting that the 
STK38 and PINK1/Parkin/USP30 pathways can at least 
in part be interlinked in the context of the survival of 
Ras-transformed human cells. In this regard, we further 
observed that co-depletion of STK38 and USP30 was 
sufficient to fully restore total mitochondrial mass (Figure 
7G) and mitochondrial ROS levels (Figure 7H) to normal 
values as observed in control cells. Taken together, these 
data indicate that mitophagy in general appears to be 
important for the survival of detached Ras-transformed 
human cells, with STK38 and established regulators of 
mitophagy supporting the anchorage-independent growth 
of Ras-transformed cells.
DISCUSSION
Here, we report STK38 as a key mediator of Ras-
driven transformation of human cells. STK38 knockdown 
causes impaired anoikis resistance, anchorage-independent 
soft agar growth, and xenograft in vivo growth of Ras-
transformed cells (Figure 1, 2, 3). STK38 supports 
autophagy and mitophagy in detached Ras-transformed 
cells (Figure 4, 6), thereby promoting cancer cell survival 
by facilitating anoikis resistance. The Ral-Exocyst-
STK38 pathway promotes anchorage-independent growth 
downstream of oncogenic Ras (Figure 1, 5, Supplementary 
Figure S8, S9). Specifically, RalA and RalB are at least 
in part critical for detachment-induced STK38 activation, 
detachment-induced autophagy, and anchorage-independent 
growth of Ras-transformed cells (Figure 5). However, 
only RalB appears to be important for anoikis resistance 
and efficient clearance of mitochondria in detached cells 
(Figure 5, Supplementary Figure S13). Thus, RalA and RalB 
seem to have distinct roles in Ras-driven transformation 
using STK38 as a downstream effector. Therefore, how the 
RalB-STK38 axis is directly regulated by upstream factors, 
and how STK38 connects Ras signalling to downstream 
effectors deserves future investigation, in order to further 
expand our understanding of the autophagic function(s) of 
STK38 in Ras-transformed cells.
Little is known about the complex crosstalk 
between anoikis and detachment-induced autophagy 
[3, 4]. Typically, autophagy antagonises apoptosis, and 
apoptosis induction reduces autophagy. In line with this 
general model, our data indicate that upon loss of ECM-
cell contact STK38 seems to function as a suppressor of 
anoikis while promoting detachment-induced autophagy 
(Figure 4). Considering that in adherent human cells 
STK38 can act as a pro-apoptotic kinase [28–32], this 
cytoprotective role of STK38 was unanticipated. Instead of 
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Figure 7: The mitophagy regulators Parkin, PINK1 and USP30 are linked to STK38 in supporting anchorage-
independent growth of Ras-transformed human cells. A-C. Western blot analysis of HK-RasG12V cells transiently transfected 
with indicated siRNAs (A). Densitometry quantifications of immunoblots are indicated below the immunoblots (A). Cells were subjected 
to soft agar growth assays. Representative images of soft agar assays are shown (B). Histograms represent the quantification of colony 
formation in soft agar (C). Average of three independent experiments performed in duplicates is shown (C, n=3, ***p<0.001). D-F. Real-
time quantitative PCR analysis of STK38 and USP30 mRNA expression in HK-RasG12V cells transiently transfected with indicated 
siRNAs. The averaged results of triplicates are shown (D). Cells were subjected to soft agar growth assays. Representative images of soft 
agar assays are shown (E). Histograms represent the quantification of colony formation in soft agar (F). Average of three independent 
experiments performed in duplicates is shown (F, n=3, *p<0.05; ***p<0.001; ns, not significant). G, H. Cells transiently transfected with 
indicated siRNAs and grown in suspension were subjected to flow cytometry using a membrane potential-independent MitoTracker (G) or 
the MitoSOX Red dye (H). Histograms show the quantifications of total mitochondrial mass (G) and mitochondrial ROS levels (H) from 
three independent experiments (n=3, *p<0.05).
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defining, as initially anticipated, to which degree STK38 as 
a pro-apoptotic kinase opposes Ras-driven transformation, 
our study uncovered an unexpected pro-survival role of 
STK38 as a promoter of mitophagy. Thus, future studies 
of how STK38 is regulated in this context will help to 
understand how STK38 can switch from a pro-apoptotic 
role to a pro-survival function. In this regard, changes 
in the subcellular localisation patterns and/or regulatory 
binding partners of STK38 may play a role [27].
In further support of a role for STK38 as a pro-survival 
factor following ECM detachment, detached STK38-depleted 
Ras-transformed cells displayed loss of mitochondrial 
membrane potential (Figure 6, Supplementary Figure S10), 
suggesting that STK38 can prevent the accumulation of 
depolarised mitochondria. Therefore, we studied different 
mitochondrial parameters (Figure 6, Supplementary Figure 
S6, S10, S11), revealing that STK38 appears to be important 
for the removal of damaged mitochondria by mitophagy in 
Ras-transformed cells. In this regard, PINK1- or Parkin-
depleted Ras-transformed cells also displayed decreased 
anoikis resistance and anchorage-independent growth 
(Figure 7, Supplementary Figure S14), while detachment-
induced autophagy in general appeared to be unaffected by 
PINK1 knockdown (Supplementary Figure S12), which 
suggests that mitophagy is critical for anoikis resistance 
and potentially tumour formation. Even more importantly, 
depletion of USP30, a major opponent of PINK1/Parkin-
mediated mitophagy [47, 48], partially restored soft agar 
growth, and fully restored total mitochondrial mass and ROS 
levels of STK38-depleted Ras-transformed cells (Figure 7). 
These findings indicate that the STK38 and PINK1/Parkin/
USP30 pathways are potentially connected. Based on our 
findings it is likely that these pathways support the survival 
of Ras-transformed human cells by ensuring the removal 
of damaged mitochondria, which are prone to produce 
potentially toxic mitochondrial ROS [49, 50]. In this regard, 
our data (Figure 6, Supplementary Figure S6) further propose 
that STK38-mediated removal of damaged mitochondria can 
play a role in preventing the increased production of ROS, 
which has the potential to significantly decrease cancer cell 
survival [22]. Moreover, by defining STK38 as a potential 
regulator of mitophagy, our study lays a foundation for follow 
up studies to increase our understanding of how mitophagy is 
initiated and executed as well as how mitophagy can play a 
role in Ras-driven tumours. Thus, future research into these 
different aspects is warranted.
Cancer cell metabolism generally prefers aerobic 
glycolysis over mitochondrial oxidation, a phenomenon 
known as the Warburg effect [51]. In particular, cells in 
suspension increase glycolysis over glucose oxidation 
to meet their energy needs, and thereby contribute to 
anoikis resistance and the metastatic potential of cancer 
cells [52]. As a result, it is possible that STK38-mediated 
autophagy might help to meet the metabolic demands of 
Ras-transformed cells to facilitate the survival of tumour 
cells. Several observations would be supportive of this 
hypothesis: first, detachment-induced autophagy is critical 
for the survival in suspension [3, 9], second, inhibition 
of autophagy in Ras-driven cancer models can cause 
defective mitochondrial metabolism [4], and third, Ras 
signalling can re-programme cellular metabolism [53]. 
Consequently, much remains to be learned concerning 
the precise mechanisms through which autophagy 
controls metabolism [4]. In this context, future research 
may reveal that STK38-mediated autophagy can play a 
critical role in the enhanced glycolytic capacity of Ras-
transformed cells, which would help to understand how 
autophagy and glycolysis are linked. Since autophagy is 
upregulated during metastasis [4, 54], our findings further 
propose that STK38-mediated detachment-induced 
autophagy might contribute to metastasis by promoting 
anoikis resistance, which can facilitate tumour cell 
dissemination and dormancy [55]. Considering further 
that apoptotic resistance is indispensable for all steps of 
metastatic progression with anoikis resistance being the 
most critical step [55], future research in suitable animal 
models is warranted to examine whether and how STK38-
mediated autophagy can support metastasis. Such studies 
may help to develop a clear rationale for if (and when) 
pharmacological STK38 inhibition can interfere with 
metastasis.
In general, autophagy studies represent a research 
area with increasing interest regarding oncogenesis and 
cancer therapy resistance [4, 7, 8]. Thus, the definition of 
the context specific roles for autophagy in cancer and the 
regulatory signalling mechanisms is important to guide 
autophagy-based therapeutic intervention [8]. Particularly, 
the “autophagy addiction” of Ras-driven cancers might be 
exploitable by targeting autophagy. Thus, our discovery 
of STK38 as autophagy regulator in Ras-transformed 
cells may help to develop an intervention opportunity for 
Ras-driven cancers. As a protein kinase [26, 27], STK38 
represents a potentially interesting drug target to inhibit 
autophagy activity in Ras-driven cancers. Considering 
further that STK38 knockout mice are viable and fertile 
with normal life spans [28, 56] and STK38 displays 
unique features in its regulatory and catalytic domains [26, 
27], we propose that the development of pharmacological 
compounds that selectively target STK38 should be a 
feasible option for clinical approaches aiming to target 
“autophagy addicted” cancers. However, STK38 inhibitors 
will require stringent evaluation, since STK38 has other 
cellular functions [27] besides the roles described here, 
and STK38-deficiency can impair the immune system of 
mice [28, 57, 58]. Thus, it will be interesting to ascertain 
in appropriate preclinical cancer models whether selective 
and acute STK38 inhibition can be of therapeutic benefit 
to target Ras-driven cancer cells without harming healthy 
tissues.
Taken together, we define here STK38 as a facilitator 
of oncogenic Ras-driven transformation. STK38-
mediated autophagy supports “autophagy addicted” 
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Ras-transformed cells by sustaining anoikis resistance 
and anchorage-independent growth through functioning 
as effector of Ras-Ral signalling. Therefore, we provide 
here insights into a new signalling mechanism that could 
possibly be exploited for the development of novel clinical 
compounds allowing the targeted inhibition of autophagy 
in Ras-driven cancers. In this framework, our findings now 
draw attention to the importance of further understanding 
the selective vs. non-selective autophagic function(s) of 
STK38 and their upstream regulators and downstream 
effectors in a context-dependent manner.
MATERIALS AND METHODS
Tissue cell culture and drug treatments
Cells were cultured at 37°C and 5% CO2 in 
humidified chambers. HK-HT cells were grown in 
DMEM (Gibco) with 10% FBS (Gibco), 1% penicillin/
streptomycin (Invitrogen),100 µg/ml hygromycin and 
400 µg/ml neomycin [33]. Media for HK-HRasG12V 
and HK-HRasG12V/E37G cell pools were added 300 
µg/ml zeocin. HK-HA-STK38-PIF, HK-HA-STK38-
PIF/kd cell pools were added 1 µg/ml puromycin, HK-
HRasG12V cell pools stably expressing shRNAs were 
added zeocin and puromycin, and HK-HRasG12V cell 
pools stably expressing shRNAs and RNAi-resistant 
HA-STK38 were added zeocin, puromycin, and 5 g/ml 
blasticidin. HCT116, Panc1, H1299, and T24 cells were 
from ATCC and cultured in DMEM with 10% FBS and 
1% penicillin/streptomycin, except H1299 were grown in 
RPMI 1640 GlutaMAX (Invitrogen) instead of DMEM. 
Antibiotics were from Invivogen unless otherwise stated. 
For suspension culture, cells were grown attached to sub-
confluence, before culturing in complete medium at 3 × 10 
E5 cells per well on 0.02% pluronic acid-coated Ultra Low 
Attachment Surface 6-well plates (Corning). Chloroquine 
(CQ), 3-methyladenine (3-MA) and N-acetylcysteine 
(NAC) were from Sigma.
Generation of stable cell lines
For retrovirus production HEK293Tv packaging cells 
were transfected with retroviral vectors and the packaging 
plasmid pcl10A1 (NBP2-29542, Novus) using Fugene 6 
(Promega) according to manufacturer’s instructions. 48 hrs 
post-transfection viral supernatants were harvested, filtered, 
and added to the recipient cell lines in the presence of 4 
microgram per ml were used, so please put the "micro" symbol 
back. polybrene (Sigma-Aldrich). 24 hrs post-infection, 
recipient cells were selected with appropriate antibiotics.
siRNA transfections
Cells were reverse transfected with siRNAs using 
Lipofectamine RNAiMax (Invitrogen) according to 
manufacturer’s instructions. 72 hrs post-transfection, cells 
were harvested for immunoblotting or treated as defined in 
the specific sections.
Source and sequences of siRNAs
siControl non-targeting siRNA (D-001810-01-50), 
siATG5-1 ON-TARGET and siATG5 smart pool (L-
004374-00-0005) were purchased from Dharmacon. The 
remaining siRNAs were purchased from Eurogentec:
STK38-1: 5’- CCTTATCGCTCAACATGAAdTT-3’
STK38-2: 5’-CGTCGGCCATAAACAGCTAdTT-3’
STK38-3: 5’ GAGCAGGTTGGCCACATTCdTT-3’
STK38L-1: 5’-GTTACGTCGATCACAACACdTT-3’
STK38L-2: 5’-GACACCTTGACAGAAGAGGdTT-3’
RalA-1: 5’-GAGACAACTACTTCCGAAGdTT-3’
RalA-2: 5’-GACAGGTTTCTGTAGAAGAdTT-3’
RalB-1: 5’-TGACGAGTTTGTAGAAGACdTT-3’
RalB-2: 5’-CAAAGACGTGATGAGTTAATTdTT-3’
Beclin1-1: 5’-ACCGACTTGTTCCTTACGGAAdTT-3’
Beclin1-2: 5’-TGGACAGTTTGGCAATCAAdTT-3’
ATG5-2: 5’ AACCTTTGGCCTAAGAAGAAAdTT-3’
Sec5: 5’-GGTCGGAAAGACAAGGCAGdTT-3’
Exo84:  5’-CCACTTTACTCTATATTCAdTT-3’
Parkin1-1:  5’-CAGTTTGTTCACGACCCTCAAdTT-3’
Parkin1-2: 5’-CAGAGGAAAGTCACCTGCGAAdTT-3’
PINK1-1: 5’-CAAGTCCGACAACATACTTdTT-3’
PINK1-2: 5’-TAACTGCAGGCCAACACGCdTT-3’
USP30: 5’-GTGACAACTGTACAAAGATTGdTT-3’
p21/Cip1: 5’-ATAATTAAGACACACAAACdTT-3’
Cell proliferation and cell viability analyses
Cells were seeded at 8 x 10 E4 cells per well in 
6-well plates and at indicated time points counted using 
the automated ViCell-XR cell counter (Beckman Coulter). 
Cell viability was determined by trypan blue exclusion.
Soft agar assays for anchorage-independent 
growth
After trypsinization, cells were passed 4-5 times 
through a 21G syringe, before 1 x 10 E4 cells were 
resuspended in complete medium with 0.3% agarose (A2576, 
Sigma) and appropriate antibiotics, and subsequently 
cultured in 15 ml tubes (352059, BD Biosciences) overlaid 
with medium without agarose. After two weeks, agarose gels 
were very gently poured into wells of 6-well plates, colonies 
stained with 2.5 mg/ml MTT (Sigma), scanned, and finally 
quantified using the Image J software. Cell clusters of at least 
50 cells were scored as colonies.
Xenograft animal experiments
5 x 10 E6 exponentially growing cells were 
subcutaneously injected into the interscapular fat pad of 
six weeks-old female Swiss nude mice (Charles Rivers 
Oncotarget44156www.impactjournals.com/oncotarget
Laboratories, France). Tumour growth was evaluated by 
measuring two perpendicular diameters of tumours with a 
caliper three times per week. Individual tumour volumes 
were calculated as V = a × b2/2, with a being the major 
diameter, and b the minor diameter. Tumour growth 
curves were established as a function of time. Mice were 
sacrificed once tumours reached a volume of 1500 mm3. 
Experiments were performed in compliance with animal 
welfare regulations of the European Community (86/609/
EEC), the French Competent Authority, and the UKCCCR 
guidelines.
Cell cycle, apoptosis and mitochondrial 
parameter measurements by flow cytometry
To determine cell cycle profiles, cells were fixed 
in ice cold 70% EtOH/PBS, washed with PBS and 
subsequently incubated in PBS containing 50 mg/ml 
propidium iodide (PI, Sigma) and 500 units/ml RNaseA 
(Life Technologies). To measure apoptotic cells, cells were 
stained with AnnexinV-FITC antibody and PI according 
to manufacturer’s instructions (BD Pharmingen). To 
assess mitochondrial mass, cells were stained with 
the mitochondrial membrane potential-independent 
MitoTracker Green FM (Invitrogen) as instructed by 
the manufacturer. Mitochondrial membrane potential 
(ΔΨm) was tested by staining cells with JC-1 (Invitrogen) 
according to manufacturer’s instructions. ΔΨm is 
expressed as the ratio between JC-1 red fluorescence and 
JC-1 green fluorescence. The JC-1 dye exhibits potential-
dependent accumulation in mitochondria, indicated by 
a fluorescence emission shift from green (~529 nm, 
representing depolarized mitochondria) to red (~590 
nm, indicating polarized mitochondria). Mitochondrial 
depolarization is indicated by a decrease in the red/green 
fluorescence intensity ratio. Mean Fluorescence Intensity 
(MFI) was measured by flow cytometry. All samples 
were analysed using the LSRII flow cytometer (BD 
Biosciences).
Immunofluorescence microscopy, 
immunoblotting, pull down experiments, 
and densitometry analysis
Immunofluorescence (IF) and Western blot analyses 
were performed as defined [29]. IF images were acquired 
using a Zeiss Axiovert 200M Apotome microscope. For 
LB3B puncta quantifications, fields were chosen arbitrarily 
based on DAPI staining and the number of LC3 dots per 
cell was determined using Image J software. Immunoblot 
signals were visualized by enhanced chemiluminescence 
detection (Western Lightning Plus-ECL, PerkinElmer). 
Densitometric analyses of immunoblots were performed 
using the Multi Gauge software (FujiFilm). Pull downs 
were performed as reported [59] using the Ral binding 
domain (RalBD) of Sec5 (residues 1 to 99) fused to GST 
as Ral-GTP trap. Briefly, cells were lysed in lysis buffer 
(50 mM Tris pH 7.4, 150 mM NaCl, 10 mM MgCl2, 
1% Triton X-100, 0.1% SDS, freshly supplemented 
with a cocktail of proteases inhibitors and 1 mM DTT). 
Subsequently, lysates were incubated with GST-RalBD 
bound to glutathione-Sepharose for 40 minutes at 4°C, 
before washing with lysis buffer, and final analysis by 
Western blotting.
Reactive oxygen species (ROS) measurements by 
flow cytometry
To assess intracellular levels of ROS, cells were 
stained with the Carboxy-H2DCFDA dye (Invitrogen) 
according to manufacturer’s instructions. To assess 
mitochondrial ROS levels, cells were stained with 
MitoSOX Red (Invitrogen) according to manufacturer’s 
instructions.
Antibodies
For Western blotting the following primary 
antibodies were used: STK38 (H00011329-M011, 
Abnova), Cleaved-PARP (552597), Adaptin (610502), 
RalA (610222), and Ras (610002) from BD Biosciences; 
Beclin1 (3495), LC3B (2775), ATG5 (2630), RalB (3523) 
p21/Cip1 (2947), pAKT (9271), AKT (4685), pERK 
(4370), and ERK (4695) from Cell signalling; PINK1 
(ab23707), Parkin (ab15954), TOM20 (ab56783) and 
the total OXPHOS antibody cocktail (ab110411) from 
Abcam; HA (12CA5, Roche); β-Actin (A5441, Sigma-
Aldrich); and GAPDH (MAB374, Millipore). Polyclonal 
rabbit anti-T444-P and anti-STK38L antibodies have been 
described [28, 31, 60]. Rabbit polyclonal antibodies raised 
against Sec5 and Exo84 were kind gifts from Charles 
Yeaman (University of Iowa) [61]. Donkey anti-rabbit-
HRP and anti-mouse-HRP secondary antibodies were from 
Jackson Immunoresearch and GE Healthcare, respectively. 
For immunofluorescence we used anti-LC3B (5F10, 
nanoTools) as primary antibody and anti-mouse Alexa488 
(Jackson ImmunoResearch) as secondary antibody.
RNA isolation, cDNA synthesis, and real-time 
quantitative PCR gene expression analysis
Total RNAs were extracted from cells at 80% – 90% 
confluence using the RNeasy Plus Mini Kit (Qiagen). 
cDNA synthesis was performed using the iScript cDNA 
synthesis Kit (Bio-Rad) according to manufacturer’s 
protocol. qPCR was carried out in triplicates using 
validated qPCR primers (Qiagen; USP30, Hs.486434; 
STK38, Hs.409578; Sec5, Hs.484412; and GAPDH, 
Hs.544577) and the TaqMAN PCR master mix (Applied 
Biosystems) using the Chromo4 DNA Engine Peltier 
Thermal Cycler (Bio-Rad). GAPDH mRNA served as 
internal control for standardization.
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Plasmids
Retroviral plasmids encodingHRasG12V, 
HRasG12V/E37G, HA-STK38 PIF, HA-STK38 PIF/
kd, and shLUC have been reported [34, 38, 62]. To 
generate the pSuper.retro.puro_shSTK38-2 vector 
expressing shRNAs against human STK38, the following 
oligonucleotide pairs were inserted into pSuper.retro.
puro (Oligoengine) using BglII and HindIII: 5′-GATCC
CCGTCGGCCATAAACAGCTATTCAAGAGATAGCT
GTTTATGGCCGACGTTTTTGGAAA-3′ and 5′- AGC
TTTTCCAAAAACGTCGGCCATAAACAGCTATCTC
TTGAATAGCTGTTTATGGCCGACGGG-3′ targeting 
the 3’UTR of STK38. For shRNA rescue experiments, 
HA-tagged STK38 wild-type and kinase-dead (K118A) 
cDNAs were subcloned from modified pcDNA3_HA 
into modified pWZLblast using PmeI and XhoI. Modified 
pcDNA_HA was generated by inserting the following 
oligonucleotide pairs into pcDNA3 (Invitrogen) using 
HindIII and BamHI: 5′-AGCTTACGCGTGTTTAAACGG
TACCATGGCCTACCCCTACGACGTGCCCGACTACG
CCTCCCTCG-3’ and 5’-GATCCGAGGGAGGCGTAGT
CGGGCACGTCGTAGGGGTAGGCCATGGTACCGTT 
TAAACACGCGTA-3’. Modified pWZLblast was 
generated by inserting the following oligonucleotide pairs 
into pWZLblast GFP (12269, Addgene) using BamHI and 
SalI: 5′-GATCCACGCGTGTTTAAACGTTAACGAATT
CTACGTACTCGAGG -3’ and 5’-TCGACCTCGAGTAC
GTAGAATTCGTTAACGTTTAAACACGCGTG -3’. All 
constructs were confirmed by sequence analysis. Further 
details on constructs are available upon request.
Statistical analysis
Unless otherwise stated the significance of differences 
between the means or the population distributions was 
determined using two-tailed unpaired Student’s t-tests. 
For tumour volume measurements and Ral-GTP pulldown 
assays, the p-values were calculated using the Mann-
Whitney statistical test. For all tests, differences were 
considered statistically significant when p-values were 
below 0.05 (*), 0.01 (**), or 0.001 (***). In the Figures 
p-values are indicates as: *p<0.05; **p<0.01; ***p<0.001; 
ns, not significant. Error bars represent standard deviation.
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